Acta Crystallographica Section E

Structure Reports

Online

ISSN 1600-5368

Editors: **W. Clegg** and **D. G. Watson**

The triclinic form of 2,9-dichloro-5,12-dihydroquino[2,3-*b*]acridine-7,14-dithione dimethylacetamide disolvate

Takatoshi Senju, Tomonori Hoki and Jin Mizuguchi

Copyright © International Union of Crystallography

Author(s) of this paper may load this reprint on their own web site provided that this cover page is retained. Republication of this article or its storage in electronic databases or the like is not permitted without prior permission in writing from the IUCr.

Takatoshi Senju, Tomonori Hoki
and Jin Mizuguchi*

Department of Applied Physics, Graduate
School of Engineering, Yokohama National
University, Tokiwadai 79-5, Hodogaya-ku,
Yokohama 240-8501, Japan

Correspondence e-mail: mizu-j@ynu.ac.jp

Key indicators

Single-crystal X-ray study

$T = 93\text{ K}$

Mean $\sigma(\text{C}-\text{C}) = 0.005\text{ \AA}$

Disorder in solvent or counterion

R factor = 0.061

wR factor = 0.216

Data-to-parameter ratio = 12.7

For details of how these key indicators were
automatically derived from the article, see
<http://journals.iucr.org/e>.

The triclinic form of 2,9-dichloro-5,12-dihydro- quino[2,3-*b*]acridine-7,14-dithione dimethylacetamide disolvate

The title compound, $\text{C}_{20}\text{H}_{10}\text{Cl}_2\text{N}_2\text{S}_2 \cdot 2\text{C}_4\text{H}_9\text{NO}$, is a dimethylacetamide (DMA) disolvate of DTQ-Cl, which is a thionated derivative of a 2,9-dichloroquinacridone pigment. The compound shows polymorphism and this paper reports the triclinic form (space group $P\bar{1}$, $Z = 1$). The DTQ-Cl molecule is centrosymmetric and planar, while the DMA molecule is orientationally disordered. Two symmetry-related DMA molecules are hydrogen bonded *via* their O atoms to the NH groups of DTQ-Cl. The molecular plane of DMA is twisted with respect to the DTQ-Cl skeleton by $73.6(1)^\circ$.

Received 9 May 2005

Accepted 24 May 2005

Online 31 May 2005

Comment

The title compound (DTQ-Cl·2DMA), (I), is a dimethylacetamide (DMA) disolvate of DTQ-Cl, which is a thionated derivative of 2,9-dichloroquinacridone known as an industrially important red pigment (Herbst & Hunger, 1997). The background of the present study has been set out in our previous paper (Senju *et al.*, 2005). We obtained three kinds of solvated crystals of DTQ-Cl. One was isolated from a dimethylformamide solution (Senju *et al.*, 2005), and the other two polymorphic forms were obtained from one single solution in DMA. The structure of the monoclinic form, (Ia), has been reported in the preceding paper (Hoki *et al.*, 2005). The present paper deals with the structure of the triclinic form, (Ib).

Fig. 1 shows an *ORTEP* (Burnett & Johnson, 1996) plot of (Ib). The DTQ-Cl molecule is centrosymmetric and planar, as characterized by the mean deviation of $0.019\text{ \AA}$ from the least-squares plane ($\text{C1}-\text{C10}/\text{N1}$). The DMA molecule is orientationally disordered. The molecular plane of DMA is twisted with respect to the DTQ-Cl skeleton by $73.6(1)^\circ$.

Figure 1

A view of the molecular structure of (Ib), showing 50% probability displacement ellipsoids for non-H atoms. Atoms labelled with an asterisk (*) are at the symmetry position ($1 - x, 2 - y, -z$). Unlabelled atoms are related to labelled atoms by this same symmetry operator. Only the major disorder component is shown.

There are N—H...O intermolecular hydrogen bonds (Table 2) between the NH group of DTQ-Cl and the O atom of DMA. DTQ-Cl molecules are stacked parallel to each other along the *b* axis, forming one column (Fig. 2). Similarly, DMA molecules form another column sandwiched by two columns of DTQ-Cl.

Experimental

DTQ-Cl was synthesized by thionation of commercially available 2,9-dichloroquinacridone using Lawesson's reagent (Rochat *et al.*, 1988). Crystals of (I) were grown by gradual cooling of a DMA solution prepared at about 420 K. Single crystals of both monoclinic and triclinic forms were obtained at the same time from one single solution. Both crystal forms appeared dark green. However, the crystal shapes were different, being needle for (Ia) and platelet for (Ib).

Crystal data

$C_{20}H_{10}Cl_2N_2S_2 \cdot 2C_4H_9NO$

$M_r = 587.58$

Triclinic, *P*1

$a = 7.156$ (2) Å

$b = 8.941$ (3) Å

$c = 11.487$ (4) Å

$\alpha = 104.32$ (2)°

$\beta = 96.91$ (2)°

$\gamma = 107.369$ (18)°

$V = 664.5$ (4) Å³

$Z = 1$

$D_x = 1.468$ Mg m⁻³

Cu $K\alpha$ radiation

Cell parameters from 5253 reflections

$\theta = 4.1$ – 68.0 °

$\mu = 3.95$ mm⁻¹

$T = 93.1$ K

Platelet, dark green

$0.40 \times 0.40 \times 0.08$ mm

Figure 2

The molecular arrangement of DMA-solvated DTQ-Cl in (Ib). H atoms have been omitted.

Data collection

Rigaku R-Axis RAPID-F imaging-plate diffractometer

ω scans

Absorption correction: multi-scan

(*ABSCOR*; Higashi, 1995)

$T_{\min} = 0.281$, $T_{\max} = 0.729$

5955 measured reflections

2164 independent reflections

1551 reflections with $F^2 > 2\sigma(F^2)$

$R_{\text{int}} = 0.039$

$\theta_{\max} = 68.1$ °

$h = -8 \rightarrow 8$

$k = -10 \rightarrow 10$

$l = -11 \rightarrow 10$

Refinement

Refinement on F^2

$R[F^2 > 2\sigma(F^2)] = 0.061$

$wR(F^2) = 0.217$

$S = 1.18$

2164 reflections

171 parameters

H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.1319P)^2]$

where $P = (F_o^2 + 2F_c^2)/3$

$(\Delta/\sigma)_{\max} < 0.001$

$\Delta\rho_{\max} = 0.46$ e Å⁻³

$\Delta\rho_{\min} = -0.53$ e Å⁻³

Table 1

Selected geometric parameters (Å, °).

Cl1—C2	1.752 (4)	C3—C4	1.376 (5)
S1—C7	1.630 (4)	C4—C5	1.417 (5)
O1—C15	1.191 (11)	C5—C6	1.402 (6)
O1—C14	1.236 (8)	C6—C7	1.459 (5)
N1—C5	1.352 (5)	C7—C8	1.475 (5)
N1—C9	1.370 (4)	C8—C10	1.389 (5)
C1—C2	1.358 (5)	C8—C9	1.417 (6)
C1—C6	1.418 (5)	C9—C10 ⁱ	1.392 (5)
C2—C3	1.390 (6)		
C5—N1—C9	122.2 (3)	C1—C6—C7	120.3 (4)
C2—C1—C6	119.8 (4)	C6—C7—C8	114.8 (4)
C1—C2—C3	122.5 (4)	C6—C7—S1	123.1 (3)
C1—C2—Cl1	118.9 (3)	C8—C7—S1	122.1 (3)
C3—C2—Cl1	118.5 (3)	C10—C8—C9	118.4 (4)
C4—C3—C2	119.0 (4)	C10—C8—C7	121.1 (4)
C3—C4—C5	120.2 (4)	C9—C8—C7	120.5 (3)
N1—C5—C6	121.1 (3)	N1—C9—C10 ⁱ	119.6 (4)
N1—C5—C4	118.9 (4)	N1—C9—C8	120.2 (4)
C6—C5—C4	120.0 (4)	C10 ⁱ —C9—C8	120.2 (3)
C5—C6—C1	118.5 (4)	C8—C10—C9 ⁱ	121.4 (4)
C5—C6—C7	121.2 (3)		

Symmetry code: (i) $-x + 1, -y + 2, -z$.

Figure 3

A schematic representation of the orientationally disordered DMA in (Ib). (a) The major component, N2/C14 (62%). (b) The minor component, N3/C15 (38%).

Table 2

Hydrogen-bond geometry (Å, °).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
N1–H1N $\cdots$ O1	0.88	1.90	2.774 (4)	173

The planar DMA molecule has two possible orientations (Fig. 3), and the positions of not only atom O1 but also of the three methyl atoms, C11, C12 and C13, are strongly overlapped. The clearly split atoms, N2/C14 and N3/C15, were refined isotropically. The site-occupancy factor was determined by equalizing, as much as possible,

the U_{iso} parameters for the two sites, the occupancy of the major site (N2/C14) being 62%. Methyl H atoms were placed in geometrically idealized positions considering the orientational disorder of the DMA molecule, and constrained to ride on their parent C atoms, with $C-H = 0.98$ Å and $U_{\text{iso}}(H) = 1.5U_{\text{eq}}(C)$. All other H atoms were placed in geometrically idealized positions and constrained to ride on their parent atoms, with $C-H = 0.95$ Å and $N-H = 0.88$ Å, and $U_{\text{iso}}(H) = 1.2U_{\text{eq}}(\text{parent atom})$.

Data collection: *PROCESS-AUTO* (Rigaku, 1998); cell refinement: *PROCESS-AUTO*; data reduction: *CrystalStructure* (Rigaku/MSD, 2005); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEPIII* (Burnett & Johnson, 1996); software used to prepare material for publication: *CrystalStructure*.

References

- Burnett, M. N. & Johnson, C. K. (1996). *ORTEPIII*. Report ORNL-6895. Oak Ridge National Laboratory, Tennessee, USA.
- Herbst, W. & Hunger, K. (1997). *Industrial Organic Pigments*, 2nd ed. pp. 454–474. Weinheim: VCH.
- Higashi, T. (1995). *ABSCOR*. Rigaku Corporation, Tokyo, Japan.
- Hoki, T., Senju, T. & Mizuguchi, J. (2005). *Acta Cryst.* **E61**, o1927–o1929.
- Rigaku (1998). *PROCESS-AUTO*. Rigaku Corporation, Tokyo, Japan.
- Rigaku/MSD (2005). *Crystal Structure*. Version 3.7.0. Rigaku/MSD, 9009 New Trails Drive, The Woodlands, TX 77381-5209, USA.
- Rochat, A. C., Jaffe, E. E. & Mizuguchi, J. (1988). US Patent No. 4760004.
- Senju, T., Hoki, T. & Mizuguchi, J. (2005). *Acta Cryst.* **E61**, o1617–o1619.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.